Grim-19 expressed by recombinant adenovirus for esophageal neoplasm target therapy

Song,Jianxiang; Shi,Woda; Wang,Wencai; Zhang,Yajun; Zheng,Shiying

doi:10.3892/mmr.2018.8638

Grim-19 expressed by recombinant adenovirus for esophageal neoplasm target therapy

Authors:
- Jianxiang Song
- Woda Shi
- Wencai Wang
- Yajun Zhang
- Shiying Zheng
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Cardiothoracic Surgery, The Third People's Hospital, Yancheng, Jiangsu 224001, P.R. China
Published online on: February 27, 2018 https://doi.org/10.3892/mmr.2018.8638
Pages: 6667-6674

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EA) are the two most common types of esophageal cancer, which is the sixth highest cause of cancer‑associated mortality and the eighth most common cancer worldwide. Gene associated with retinoid‑interferon (IFN)‑induced mortality‑19 (Grim‑19) is reported to be a cell death activator that may be used to define mechanisms involved in IFN‑β‑ and retinoic acid‑induced cell death and apoptosis in a number of tumor cell lines. The present study constructed a recombinant adenovirus expressing Grim‑19 (rAd‑Grim‑19) and investigated its therapeutic outcomes in ESCC cells and tumor‑bearing mice. Grim‑19 expression was detected in EC‑109 (ESCC) cells by reverse transcription‑quantitative polymerase chain reaction and western blot analysis. Tumor cell death and apoptosis induced by rAd‑Grim‑19 in EC‑109 cells were analyzed by flow cytometry. The inhibitory effects of rAd‑Grim‑19 on EC‑109 growth were determined by MTT assays. Furthermore, the therapeutic effects of rAd‑Grim‑19 were investigated in EC‑109‑bearing mice. The results demonstrated that Grim‑19 mRNA and protein expression was downregulated in EC‑109 esophageal carcinoma cells compared with Het‑1A normal esophageal epithelial cells. In addition, EC‑109 cells exhibited a significant reduction in tumor cell growth in the rAd‑Grim‑19 group compared with the control groups. Furthermore, rAd‑Grim‑19 increased EC‑109 cell apoptosis compared with the control group. These results indicated that rAd-Grim-19 may regulate tumor cell growth and apoptosis. Additionally, the results demonstrated that rAd‑Grim‑19 led to beneficial outcomes and prolonged the survival of esophageal tumor‑bearing mice. In conclusion, the present study demonstrated that rAd‑Grim‑19 may have potential as an antitumor agent for esophageal neoplasms and may therefore be beneficial for patients with esophageal neoplasms.

View Figures

View References

1	Straatman J, Joosten PJ, Terwee CB, Cuesta MA, Jansma EP and van der Peet DL: Systematic review of patient-reported outcome measures in the surgical treatment of patients with esophageal cancer. Dis Esophagus. 29:760–772. 2016. View Article : Google Scholar : PubMed/NCBI
2	Fahey PP, Mallitt KA, Astell-Burt T, Stone G and Whiteman DC: Impact of pre-diagnosis behavior on risk of death from esophageal cancer: A systematic review and meta-analysis. Cancer Causes Control. 26:1365–1373. 2015. View Article : Google Scholar : PubMed/NCBI
3	Yodying H, Matsuda A, Miyashita M, Matsumoto S, Sakurazawa N, Yamada M and Uchida E: Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: A systematic review and meta-analysis. Ann Surg Oncol. 23:646–654. 2016. View Article : Google Scholar : PubMed/NCBI
4	Parry K, Ruurda JP, van der Sluis PC and van Hillegersberg R: Current status of laparoscopic transhiatal esophagectomy for esophageal cancer patients: A systematic review of the literature. Dis Esophagus. 30:1–7. 2017.PubMed/NCBI
5	Gong J, Huang Z and Huo JR: Involvement of F-box proteins in esophageal cancer (Review). Int J Oncol. 48:886–894. 2016. View Article : Google Scholar : PubMed/NCBI
6	Tian X, Zhou JG, Zeng Z, Shuai T, Yi LJ, Ma L, Wang Y, Cao H and Song GM: Cetuximab in patients with esophageal cancer: A systematic review and meta-analysis of randomized controlled trials. Med Oncol. 32:1272015. View Article : Google Scholar : PubMed/NCBI
7	Du D, Song T, Liang X, Fang M and Wu S: Concurrent chemoradiotherapy with elective lymph node irradiation for esophageal cancer: A systemic review and pooled analysis of the literature. Dis Esophagus. 30:1–9. 2017.
8	Goense L, van Rossum PS, Reitsma JB, Lam MG, Meijer GJ, van Vulpen M, Ruurda JP and van Hillegersberg R: Diagnostic performance of ¹⁸F-FDG PET and PET/CT for the detection of recurrent esophageal cancer after treatment with curative intent: A systematic review and meta-analysis. J Nucl Med. 56:995–1002. 2015. View Article : Google Scholar : PubMed/NCBI
9	Chung CS, Lo WC, Lee YC, Wu MS, Wang HP and Liao LJ: Image-enhanced endoscopy for detection of second primary neoplasm in patients with esophageal and head and neck cancer: A systematic review and meta-analysis. Head Neck. 38 Suppl 1:E2343–E2349. 2016. View Article : Google Scholar : PubMed/NCBI
10	Koo J, Wang X, Owonikoko TK, Ramalingam SS, Khuri FR and Sun SY: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget. 6:8974–8987. 2015. View Article : Google Scholar : PubMed/NCBI
11	Bahlawane C, Eulenfeld R, Wiesinger MY, Wang J, Muller A, Girod A, Nazarov PV, Felsch K, Vallar L, Sauter T, et al: Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics. Cell Commun Signal. 13:212015. View Article : Google Scholar : PubMed/NCBI
12	Hakimi R: Treatment of a questionable prostate carcinoma recurrence with oncolytic viruses, dendritic cells and heat shock proteins in established naturopathy practice. Versicherungsmedizin. 64:87–88. 2012.(In German). PubMed/NCBI
13	Kalakonda S, Nallar SC, Jaber S, Keay SK, Rorke E, Munivenkatappa R, Lindner DJ, Fiskum GM and Kalvakolanu DV: Monoallelic loss of tumor suppressor GRIM-19 promotes tumorigenesis in mice. Proc Natl Acad Sci USA. 110:pp. E4213–E4222. 2013; View Article : Google Scholar : PubMed/NCBI
14	Wen LJ, Gao LF, Jin CS, Zhang HJ, Ji K, Yang JP, Zhao XJ, Wen MJ and Guan GF: Small interfering RNA survivin and GRIM-19 co-expression salmonella plasmid inhibited the growth of laryngeal cancer cells in vitro and in vivo. Int J Clin Exp Pathol. 6:2071–2081. 2013.PubMed/NCBI
15	Li M, Li Z, Liang C, Han C, Huang W and Sun F: Upregulation of GRIM-19 suppresses the growth of oral squamous cell carcinoma in vitro and in vivo. Oncol Rep. 32:2183–2190. 2014. View Article : Google Scholar : PubMed/NCBI
16	Kalakonda S, Nallar SC, Lindner DJ, Sun P, Lorenz RR, Lamarre E, Reddy SP and Kalvakolanu DV: GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis. Oncogene. 33:3195–3204. 2014. View Article : Google Scholar : PubMed/NCBI
17	Cheng Y, Zhang HY, Zhou Y, Tao F and Yu YH: Decreased expression of GRIM-19 and its association with high-risk HPV infection in cervical squamous intraepithelial neoplasias and cancer. Clin Invest Med. 37:E77–E84. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z, Qian C and Liu X: A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene. 23:457–464. 2004. View Article : Google Scholar : PubMed/NCBI
19	Li G, Jiang P, Li Y, Wang X, Huang J, Du Y and Zeshan B: Effective suppression of replication of porcine reproductive and respiratory syndrome virus by adenovirus-mediated small interfering RNAs targeting ORF1b, 5 and 7 genes. J Virol Methods. 157:40–46. 2009. View Article : Google Scholar : PubMed/NCBI
20	Hernández-Alcoceba R, Sangro B and Prieto J: Gene therapy of liver cancer. Ann Hepatol. 6:5–14. 2007.PubMed/NCBI
21	Woodger T: Restrainers in laboratory animal research. Lab Anim (NY). 45:310–311. 2016. View Article : Google Scholar : PubMed/NCBI
22	Tomioka R: Expression of EGFP by adenovirus-mediated gene transfer in the central nervous system. Methods Mol Biol. 515:97–106. 2009. View Article : Google Scholar : PubMed/NCBI
23	Yan F, Zheng Y and Huang L: Adenovirus-mediated combined anti-angiogenic and pro-apoptotic gene therapy enhances antitumor efficacy in hepatocellular carcinoma. Oncol Lett. 5:348–354. 2013. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Chan YS, Wong JH, Fang EF, Pan W and Ng TB: Isolation of a glucosamine binding leguminous lectin with mitogenic activity towards splenocytes and anti-proliferative activity towards tumor cells. PLoS One. 7:e389612012. View Article : Google Scholar : PubMed/NCBI
26	Bustos-Valenzuela JC, Halcsik E, Bassi EJ, Demasi MA, Granjeiro JM and Sogayar MC: Expression, purification, bioactivity, and partial characterization of a recombinant human bone morphogenetic protein-7 produced in human 293T cells. Mol Biotechnol. 46:118–126. 2010. View Article : Google Scholar : PubMed/NCBI
27	Greaves MF and Brown G: Purification of human T and B lymphocytes. J Immunol. 112:420–423. 1974.PubMed/NCBI
28	Zamarin D, Vigil A, Kelly K, Garcia-Sastre A and Fong Y: Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 16:796–804. 2009. View Article : Google Scholar : PubMed/NCBI
29	Jang BI and Hwang MJ: Do esophageal squamous cell carcinoma patients have an increased risk of coexisting colorectal neoplasms? Gut Liver. 10:6–7. 2016. View Article : Google Scholar : PubMed/NCBI
30	Law S and Wong J: Lymph node dissection in surgical treatment of esophageal neoplasms. Surg Oncol Clin N Am. 16:115–131. 2007. View Article : Google Scholar : PubMed/NCBI
31	Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K and Shridhar R: Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. J Gastrointest Oncol. 6:39–44. 2015.PubMed/NCBI
32	Cottreau J, Gruchy S, Kamionek M, Lauwers GY and Arnason T: Prevalence of oesophageal epidermoid metaplasia in 1048 consecutive patients and 58 patients with squamous neoplasms. Histopathology. 68:988–995. 2016. View Article : Google Scholar : PubMed/NCBI
33	Aksel' EM, Davydov MI and Ushakova TI: Statistics of lung, stomach and esophageal cancer: Status of oncological care, morbidity and mortality. Vestn Ross Akad Med Nauk. 61–65. 2001.(In Russian).
34	Kalakonda S, Nallar SC, Lindner DJ, Hu J, Reddy SP and Kalvakolanu DV: Tumor-suppressive activity of the cell death activator GRIM-19 on a constitutively active signal transducer and activator of transcription 3. Cancer Res. 67:6212–6220. 2007. View Article : Google Scholar : PubMed/NCBI
35	Gortat A, San-Roman MJ, Vannier C and Schmidt AA: Single point mutation in Bin/Amphiphysin/Rvs (BAR) sequence of endophilin impairs dimerization, membrane shaping, and Src homology 3 domain-mediated partnership. J Biol Chem. 287:4232–4247. 2012. View Article : Google Scholar : PubMed/NCBI
36	Kalakonda S, Nallar SC, Gong P, Lindner DJ, Goldblum SE, Reddy SP and Kalvakolanu DV: Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels. Am J Pathol. 171:1352–1368. 2007. View Article : Google Scholar : PubMed/NCBI
37	Sinkovics JG and Horvath JC: Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz). 56 Suppl 1:3S–59S. 2008. View Article : Google Scholar : PubMed/NCBI
38	Zhang MM, Yan LN, Li DH, Gou XH, Liu JW, Su Z, Han L and Zhao LY: Inhibition of adenovirus-mediated gene transfer of antisense matrix metalloproteinase-2 on hepatocellular carcinoma growth in vivo. Zhonghua Gan Zang Bing Za Zhi. 13:671–674. 2005.(In Chinese). PubMed/NCBI
39	Alchanati I, Nallar SC, Sun P, Gao L, Hu J, Stein A, Yakirevich E, Konforty D, Alroy I, Zhao X, et al: A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene. 25:7138–7147. 2006. View Article : Google Scholar : PubMed/NCBI
40	Chidambaram NV, Angell JE, Ling W, Hofmann ER and Kalvakolanu DV: Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res. 20:661–665. 2000. View Article : Google Scholar : PubMed/NCBI
41	Zhang XY, Li M, Sun K, Chen XJ, Meng J, Wu L, Zhang P, Tong X and Jiang WW: Decreased expression of GRIM-19 by DNA hypermethylation promotes aerobic glycolysis and cell proliferation in head and neck squamous cell carcinoma. Oncotarget. 6:101–115. 2015.PubMed/NCBI
42	Chao L, Wang X, Yang Y, Cui W, Xu J, Chen H, Hao A and Deng X: Downregulation of gene expression and activity of GRIM-19 affects mouse oocyte viability, maturation, embryo development and implantation. J Assist Reprod Genet. 32:461–470. 2015. View Article : Google Scholar : PubMed/NCBI